PT Telekomunikasi Indonesia Tbk vs State Street SPDR S&P Biotech ETF — how do they compare? PT Telekomunikasi Indonesia Tbk trades at $12.81 (market cap $12.43B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: PT Telekomunikasi Indonesia Tbk is the larger of the two by market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.48% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold PT Telekomunikasi Indonesia Tbk for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TLK | XBI | |
|---|---|---|
Market Cap | $12.43B | $10.11B |
Volume | 1,067,041 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $23.43 | $169.55 |
52-Week Low | $12.42 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $13.80B | — |
Dividend Yield | 9.48% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →